A Phase 1/2 open-label clinical study to evaluate the safety and preliminary efficacy of AVB-101 in people with a genetic sub-type of frontotemporal dementia (FTD-GRN).

Frontotemporal dementia with progranulin mutations research (FTD-GRN)

DOWNLOAD FACT SHEET

WHO CAN PARTICIPATE?

  • People between the ages of 30 and 75, diagnosed with FTD and a confirmed GRN mutation will be included in this study.
  • To help support you, a caregiver/study partner should accompany you to all study visits, including surgery.
  • There are other criteria that determine eligibility, which may be discussed with a healthcare provider.
  • Further details about this study can be found at clinicaltrials.gov

ASPIRE-FTD is currently enrolling participants at the following sites. For more information and trial site contact details please visit clinicaltrials.gov

In the coming months we will be updating this list as more sites become active.

You can also contact AviadoBio by phone +44 (0) 203 089 7917 or by email clinicaltrials@aviadobio.com

USA

Columbus, Ohio
-The Ohio State University (OSU) Wexner Medical Center

NETHERLANDS

Amsterdam
-Amsterdam UMC

SPAIN

Barcelona
-Hospital Clinic Barcelona

Valencia
-Hospital Universitari i Politecnic La Fe

POLAND

Katowice
-Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
-Uniwersyteckie Centrum Kliniczne, SUM w Katowicach
-NEURO-CARE Sp. z o.o. Sp. Komandytowa

Warsaw
-Mazowiecki Szpital Brodnowski Sp z.o.o
-Centrum Medyczne NeuroProtect Sp z.o.o

Szczecin
-Euromedis Sp. z.o.o.

What does study participation involve?

Study participation involves visiting a clinical trial site at different points during the study for screening and follow up, and visiting an expert neurosurgical site for one-time dosing of AVB-101.

Aviadobio team david cooper

“Being relentless means always striving for the best implementation of our plans and ensuring we deliver as individuals, and as a company as whole. We know that patients have limited options and time. Even when the path may not be clear, we navigate a way forward by being bold and tenacious in our decision making.”

David Cooper

Chief Medical Officer